San Francisco, California (ots) - --Results Establish Safety, Tolerability, Lack of Immunogenicity and PK/PD Profile for First Anticalin in a Clinical Setting-- Pieris AG presented the results of the Company?s first clinical evaluation of its most advanced Anticalin®, PRS-050, an anti-VEGF targeted protein ...
Freising (ots) - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris' proprietary hepcidin antagonist program, the company announced today the positive strategic impact of the grant funding on its proprietary Anticalin pipeline. ...
Freising, Germany (ots) - - Consortium Will Receive Six Million Euro from Seventh Framework Programme The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining and completing initial clinical development of a novel Anticalin® ...
Zejtun, Malta (ots) - "We know Libya is faced with shortages of essential supplies. That's why Actavis donates EUR 2M worth of medicines to Libya now. The goods will leave Malta on Sunday and arrive in Tripoli during next week", said Actavis CEO Claudio Albrecht. "Actavis is one of the world's largest generic pharmaceutical players and takes its social responsibility very seriously." Mr. Albrecht emphasized the role of ...
Ittigen/Bern, Switzerland (ots) - Pevion Biotech AG today announced latest results from the ongoing clinical study of its therapeutic Candida vaccine PEV7, showing high levels of specific antibodies and a 100% mucosal immune response rate. The announcement further included the results of the largest, international ...
Roche Professional Diagnostics
Rotkreuz, Switzerland/Asnieres, France (ots) - Roche Professional Diagnostics and Diagnostica Stago announced today that the companies have decided to pursue separate paths in the business of Laboratory Coagulation in the territories where Roche distributed the Stago product range. The exclusive sales of Stago products by Roche will continue throughout the entire year of 2011. With the exception of Japan where Roche ...
Lugano, Switzerland and Greifswald, Germany (ots) - Helsinn Healthcare SA, Switzerland and Riemser Arzneimittel AG, German licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announce today the signing of a licensing agreement granting Riemser the commercialization rights for a ...
Lugano, Switerland (ots) - The Company has entered the Phase III clinical program for both its investigational medications anamorelin, in non-small cell lung cancer-associated anorexia/cachexia, and netupitant + palonosetron oral fixed-dose combination in chemotherapy-induced nausea and vomiting (CINV) Helsinn, the Swiss pharmaceutical Group, global leader in the segment of the prevention of chemotherapy-induced nausea ...
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and ...
Ittigen/Bern, Switzerland (ots) - Pevion Biotech AG today announced that the company has granted to CSL Limited a right of first refusal for the commercialization of its therapeutic Candida vaccine in Australia and New Zealand. At the same time, both companies signed a long-term supply agreement under which CSL shall supply to Pevion components for its virosomal vaccines. CSL, Australia's leading biopharmaceutical ...
Zurich, Switzerland (ots) - New technology expands treatment options for patient with refractory ascites due to liver cirrhosis. Dr. Farzana Malik joins as Vice President of Market Access and Reimbursement. Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump System. Over the coming months, the company will ...
Amsterdam, The Netherlands (ots) - New data presented at the 14th World Conference on Lung Cancer in Amsterdam, The Netherlands, show the efficacy of the 2nd generation 5-HT3 receptor antagonist alone and in combination with aprepitant New data on the 2nd generation 5-HT3 receptor antagonist palonosetron, in the ...
European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
Prague (ots) - The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatin leads to a significant reduction in major atherosclerotic events among CKD-patients. Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract ...
European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
Prague, Czech Republic (ots) - The randomised, double-blind, placebo-controlled multi-centre study (abstract no. 2511) investigated the efficacy and safety of the monoclonal antibody rituximab (RTX) in 197 ANCA-associated vasculitis (AAV) patients. This study showed that in patients with severe AAV a single course ...
Freising (ots) - Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood. PRS-080 showcases Anticalins' ability to encapsulate small targets like hepcidin ...
Lugano, Switzerland/Sandpoint, ID (ots) - Helsinn Group makes an equity investment for a minority interest in Thorne Research, Inc. and plans to jointly commercialize nutritional supplement products with initial focus on meeting the needs of people living with cancer Helsinn Group a rapidly growing pharmaceutical ...
WMDO SA - World Medical Device Organization
Helsinki (ots) - (Jan. 11, 2011) The National Association Representing the Entire Finnish Health Technology Sector Will Now Offer its Members Convenient Online Training Built Specifically for Medical Device Professionals The Finnish Health Technology Association (FiHTA) and the World Medical Device Organization ...
Ittigen / Berne, Switzerland (ots) - Pevion Biotech AG today announced that Jean-Paul Prieels has joined its Board of Directors. Until January 2011, Dr. Prieels was Senior Vice President Research and Development at GlaxoSmithKline Biologicals. Jean-Paul Prieels joined GlaxoSmithKline Biologicals in 1987 as Associate ...
Lugano, Switzerland/Tokyo, Japan (ots) - License Agreement for Japan on Potential New Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) Helsinn Group of Switzerland and Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announce today the signing on April 12, of a licensing agreement granting Taiho the development and ...
WMDO SA - World Medical Device Organization
Ecublens, Switzerland / Minneapolis, MN (ots) - WMDO (World Medical Device Organization), the leading global provider of innovative online training for medical device professionals, announced today that it has achieved its 100th online course. Excellent reviews from industry analysts, trade associations and users in recent months have enabled WMDO to leverage growing ...
Basel (ots) - The majority of the direct descendants of company founder Fritz Hoffmann-La Roche have decided to continue the shareholder pooling agreement existing since 1948 with a modified shareholder composition. A charitable foundation established by pool members has been admitted to the pool. Maja Oeri has decided to leave the pool. The pool therefore now has 45,01 % of the votes in Roche but will ensure ...
Lugano, Switzerland/Woodcliff Lake, NJ (ots) - Helsinn Group and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the safety and efficacy protocols for Phase III trials with an investigational oral fixed-dose combination of netupitant and palonosetron in the prevention ...
San Francisco, USA and Freising, Germany (ots) - Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates to Takeda, both companies announced today. The deal initially will focus on first-in-class drug discovery efforts ...
Lugano, Switzerland (ots) - Helsinn Birex Pharmaceuticals Ltd, has been assigned world-wide rights, title and interest in Klean-Prep®, excluding Canada, and an exclusive license for the U.S. Helsinn, a pharmaceutical group based in Lugano, Switzerland today announced that it has entered into an agreement ...
Ittigen, Berne (ots) - Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women ...
Bern (ots) - Lonza AG in Visp has entered into a partnership with BKW FMB Energy Ltd (BKW) in the field of energy logistics and procurement management. Lonza plans to purchase its energy - around 500 GWh per year - on the free market in future, and has selected BKW as its partner of preference. BKW has contracted to support Lonza AG with its energy procurement strategy and sustainably implement the related ...
Lugoano, Switzerland/Melbourne, Australia (ots) - Australians can now access a new drug to prevent acute (and delayed phase) nausea and vomiting which may occur in cancer patients undergoing chemotherapy1. This follows an agreement between the Swiss pharmaceutical group Helsinn and Specialised Therapeutics ...
Lugano (ots) - New data presented at the ESMO Milan 2010 Congress show a better control of nausea and vomiting with palonosetron versus granisetron in patients undergoing cisplatin or anthracycline plus cyclophosphamide based regimens. Palonosetron superior efficacy is statistically significant in nausea control, following Highly Emetogenic Chemotherapy, in the ...
Freising-Weihenstephan (ots) - Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), under which Pieris will apply its proprietary Anticalin technology to ...
Lugano (ots) - The Minister for Finance, Mr. Brian Lenihan T.D. today performed the official opening of the centre which will play a significant role in Helsinn group's pipeline of new products. The Swiss pharmaceutical group Helsinn announced the official opening, performed today by the Minister for Finance, Mr. Brian Lenihan T.D, of its new R&D Centre of ...